To study Response Rates in Newly Diagnosed Elderly Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Hypomethylating Agent
Latest Information Update: 09 Dec 2019
At a glance
- Drugs Venetoclax (Primary) ; Azacitidine; Decitabine
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Therapeutic Use
Most Recent Events
- 09 Dec 2019 New trial record
- 06 Nov 2019 Results (N=400), assessing efficacy when Venetoclax combined with Hypomethylating agent in newly diagnosed elderly patients with Myelodysplastic Syndrome, released at the 61st Annual Meeting and Exposition of the American Society of Hematology